Colchicine with Infliximab Compared to Infliximab in Hospitalized Patients with COVID-19 Pneumonia: An Open-label Randomized Trial
Mahdi Yadollahzadeh, Somayyeh Nasiripour, Najmeh Moradi Shahrbabak, Nader Rezaie, Mohsen Farrokhpour, Mehdi Azimi, Shirin Izadi, Farhad Zamani, Maryam Farasatinasab, Hootan Diba
Coronaviruses, doi:10.2174/0126667975271636231109051950
Background: Anti-inflammatory agents have been proposed to improve oxygenation and mortality rates in severe COVID-19 pneumonia. This study has assessed the impact of colchicine as a coadjuvant inflammatory agent to infliximab in adults hospitalized with severe COVID-19 pneumonia.
Method: In this randomized, open-label clinical trial, 63 severe COVID-19 pneumonia patients according to the criteria of the National Institutes of Health, 18 to 85 years old, with an increase in TNF-α and IL-6 levels, were randomized to receive colchicine 1 mg for 7 days and infliximab as a single dose of 300 mg on the first day of treatment or infliximab as a single dose of 300 mg on the first day. The primary outcomes assessed were oxygenation parameters (PaO2/FiO2 ratio and lung infiltrate) after seven days, ICU and hospital length of stay, and in-hospital mortality rates. Secondary outcomes included laboratory data and drug safety after 7 days. Result: 52 patients with similar baseline characteristics completed the study. There were no significant differences in oxygenation parameters (PaO2/FiO2 ratio and lung infiltrate) after seven days, median ICU and hospital length of stay, and in-hospital mortality rates between the two groups. Laboratory data showed no differences between both the groups seven days after the treatment. Also, no serious side effects were observed during the study among the two groups, except for one patient, who experienced diarrhea.
Conclusion: Our results cannot support the addition of colchicine to promote the improvement of clinical outcomes in severe COVID-19 pneumonia.
CONFLICT OF INTEREST The authors declare no conflict of interest, financial or otherwise.
References
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 randomized clinical trial, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.13136Farrokhpour, Rezaie, Moradi, Infliximab and intravenous gammaglobulin in hospitalized severe covid-19 patients in intensive care unit, Arch Iran Med,
doi:10.34172/aim.2021.22PMID:33636983Fisher, Veenith, Slade, Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): A randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial, Lancet Respir Med,
doi:10.1016/S2213-2600(21)00460-4PMID:34922649Huang, C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: A meta-analysis, Ther Adv Respir Dis
Kow, Lee, Ramachandram, Hasan, Ming et al., The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: A meta-analysis of randomized trials,
doi:10.1002/iid3.562Lim, Pranata, Huang, Yonas, Soeroto et al., Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: Systematic review and meta-analysis, Can J Kidney Heal Dis
Manenti, Maggiore, Fiaccadori, Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study, PLoS One,
doi:10.1371/journal.pone.0248276Nawangsih, Kusmala, Rakhmat, Colchicine and mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and metaregression, Int Immunopharmacol,
doi:10.1016/j.intimp.2021.107723Patel, Wadhwa, Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19, Biomed Pharmacother,
doi:10.1016/j.biopha.2021.111785Peter, Mark, Enti, Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial, MedRxiv
Salehzadeh, Pourfarzi, Ataei, The impact of colchicine on the COVID-19 patients; a clinical trial study, Res Square,
doi:10.21203/rs.3.rs-69374/v1Stallmach, Kortgen, Gonnert, Coldewey, Reuken et al., Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series, Crit Care,
doi:10.1186/s13054-020-03158-0PMID:32680535Vrachatis, Giannopoulos, Giotaki, Impact of colchicine on mortality in patients with COVID-19: A metaanalysis, Hellenic J Cardiol,
doi:10.1016/j.hjc.2020.11.012Yonas, Alwi, Pranata, Elevated interleukin levels are associated with higher severity and mortality in COVID 19 -A systematic review, meta-analysis, and meta-regression, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.11.011{ 'indexed': {'date-parts': [[2024, 3, 30]], 'date-time': '2024-03-30T12:40:50Z', 'timestamp': 1711802450071},
'reference-count': 0,
'publisher': 'Bentham Science Publishers Ltd.',
'issue': '1',
'content-domain': {'domain': ['eurekaselect.com'], 'crossmark-restriction': True},
'published-print': {'date-parts': [[2024, 2]]},
'abstract': '<jats:sec>\n'
'<jats:title>Background:</jats:title>\n'
'<jats:p>Anti-inflammatory agents have been proposed to improve oxygenation and\n'
'mortality rates in severe COVID-19 pneumonia. This study has assessed the impact of '
'colchicine as\n'
'a coadjuvant inflammatory agent to infliximab in adults hospitalized with severe COVID-19 '
'pneumonia.</jats:p>\n'
'</jats:sec>\n'
'<jats:sec>\n'
'<jats:title>Method:</jats:title>\n'
'<jats:p>In this randomized, open-label clinical trial, 63 severe COVID-19 pneumonia patients '
'according\n'
'to the criteria of the National Institutes of Health, 18 to 85 years old, with an increase '
'in\n'
'TNF-α and IL-6 levels, were randomized to receive colchicine 1 mg for 7 days and infliximab '
'as a\n'
'single dose of 300 mg on the first day of treatment or infliximab as a single dose of 300 mg '
'on the\n'
'first day. The primary outcomes assessed were oxygenation parameters (PaO2/FiO2 ratio and '
'lung\n'
'infiltrate) after seven days, ICU and hospital length of stay, and in-hospital mortality '
'rates. Secondary\n'
'outcomes included laboratory data and drug safety after 7 days.</jats:p>\n'
'</jats:sec>\n'
'<jats:sec>\n'
'<jats:title>Result:</jats:title>\n'
'<jats:p>52 patients with similar baseline characteristics completed the study. There were no '
'significant\n'
'differences in oxygenation parameters (PaO2/FiO2 ratio and lung infiltrate) after seven '
'days,\n'
'median ICU and hospital length of stay, and in-hospital mortality rates between the two '
'groups. Laboratory\n'
'data showed no differences between both the groups seven days after the treatment. Also,\n'
'no serious side effects were observed during the study among the two groups, except for one '
'patient,\n'
'who experienced diarrhea.</jats:p>\n'
'</jats:sec>\n'
'<jats:sec>\n'
'<jats:title>Conclusion:</jats:title>\n'
'<jats:p>Our results cannot support the addition of colchicine to promote the improvement of\n'
'clinical outcomes in severe COVID-19 pneumonia.</jats:p>\n'
'</jats:sec>',
'DOI': '10.2174/0126667975271636231109051950',
'type': 'journal-article',
'created': { 'date-parts': [[2023, 11, 15]],
'date-time': '2023-11-15T14:05:59Z',
'timestamp': 1700057159000},
'update-policy': 'http://dx.doi.org/10.2174/bsp_crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Colchicine with Infliximab Compared to Infliximab in Hospitalized\n'
'Patients with COVID-19 Pneumonia: An Open-label Randomized Trial',
'prefix': '10.2174',
'volume': '5',
'author': [ { 'given': 'Mahdi',
'family': 'Yadollahzadeh',
'sequence': 'first',
'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar '
'Medical and Educational Hospital, Iran University of\n'
'Medical Sciences, Tehran, Iran'}]},
{ 'given': 'Somayyeh',
'family': 'Nasiripour',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Clinical Pharmacy, Rasul-e Akram Hospital, Iran '
'University of\n'
'Medical Sciences, Iran'}]},
{ 'given': 'Najmeh',
'family': 'Moradi Shahrbabak',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar '
'Medical and Educational Hospital, Iran University of\n'
'Medical Sciences, Tehran, Iran'}]},
{ 'given': 'Nader',
'family': 'Rezaie',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar '
'Medical and Educational Hospital, Iran University of\n'
'Medical Sciences, Tehran, Iran'}]},
{ 'given': 'Mohsen',
'family': 'Farrokhpour',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar '
'Medical and Educational Hospital, Iran University of\n'
'Medical Sciences, Tehran, Iran'}]},
{ 'given': 'Mehdi',
'family': 'Azimi',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar '
'Medical and Educational Hospital, Iran University of\n'
'Medical Sciences, Tehran, Iran'}]},
{ 'given': 'Shirin',
'family': 'Izadi',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar '
'Medical and Educational Hospital, Iran University of\n'
'Medical Sciences, Tehran, Iran'}]},
{ 'given': 'Farhad',
'family': 'Zamani',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, Gastrointestinal & Liver '
'Disease Research Center\n'
'(GILDRC), Firoozgar Hospital, Iran University of Medical '
'Sciences, Tehran, Iran'}]},
{ 'given': 'Maryam',
'family': 'Farasatinasab',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Clinical Pharmacy,\n'
'School of Pharmacy‐International Campus, Firoozgar Clinical '
'Research Development Center (FCRDC), Iran University\n'
'of Medical Sciences, Tehran, Iran'}]},
{ 'given': 'Hootan',
'family': 'Diba',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Clinical Pharmacy, Firoozgar Clinical Research '
'Development Center\n'
'(FCRDC), Iran University of Medical Sciences, Tehran, Iran'}]}],
'member': '965',
'container-title': 'Coronaviruses',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.eurekaselect.com/article/download?doi=10.2174/0126667975271636231109051950',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.eurekaselect.com/223567/article',
'content-type': 'text/html',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.eurekaselect.com/article/download?doi=10.2174/0126667975271636231109051950',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 3, 30]],
'date-time': '2024-03-30T12:03:36Z',
'timestamp': 1711800216000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.eurekaselect.com/223567/article'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 2]]},
'references-count': 0,
'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2024, 2]]}},
'alternative-id': ['LiveAll1'],
'URL': 'http://dx.doi.org/10.2174/0126667975271636231109051950',
'relation': {},
'ISSN': ['2666-7967'],
'subject': [ 'Infectious Diseases', 'Virology', 'Pulmonary and Respiratory Medicine',
'Immunology and Microbiology (miscellaneous)'],
'container-title-short': 'COVID',
'published': {'date-parts': [[2024, 2]]},
'assertion': [ { 'value': 'Peer Reviewed',
'order': 0,
'name': 'review_status',
'label': 'Review Status',
'group': {'name': 'peer_review_details', 'label': 'Peer Review Details'}},
{ 'value': 'Single blind',
'order': 1,
'name': 'review_process',
'label': 'Review Process',
'group': {'name': 'peer_review_details', 'label': 'Peer Review Details'}},
{ 'value': 'Checked with iThenticate',
'order': 0,
'name': 'screening_status',
'label': 'Screening Status',
'group': {'name': 'plagiarism_screening', 'label': 'Plagiarism Screening'}},
{ 'value': '2023-07-11',
'order': 0,
'name': 'received',
'label': 'Received',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2023-09-16',
'order': 1,
'name': 'revised',
'label': 'Revised',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2023-09-22',
'order': 2,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2024-03-29',
'order': 3,
'name': 'published',
'label': 'Published',
'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
